1,2-bis(3,5-dioxopiperazin-1-yl)ethane has been researched along with daunorubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creighton, AM; el-Hage, AN; Ferrans, VJ; Herman, EH; Witiak, DT | 1 |
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
2 other study(ies) available for 1,2-bis(3,5-dioxopiperazin-1-yl)ethane and daunorubicin
| Article | Year |
|---|---|
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
Topics: Animals; Body Weight; Cricetinae; Daunorubicin; Male; Mesocricetus; Piperazines; Razoxane; Stereoisomerism; Structure-Activity Relationship | 1985 |
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |